Compare Mesoblast Limited (MESO) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard Growth Index Fund ETF — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Vanguard Growth Index Fund ETF trades at $86.14. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | VUG | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $90.29 |
52-Week Low | $12.88 | $70.00 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
VUG trades at $85.32, up 0.06% with a bearish technical signal from moving averages. The ETF's low expense ratio of 0.03% and strong historical returns, including a 411% total return over the past decade per The Motley Fool (2026-07-12), highlight its cost efficiency. Recent news emphasizes its growth focus and tech-heavy holdings, with a stock split executed on 21 April 2026. Support levels are clustered around $84-$85, indicating potential near-term stability.
Outlook remains positive for long-term investors due to VUG's low-cost structure and exposure to high-growth U.S. large-cap stocks. Risks include high concentration in technology sectors and market volatility. Analyst sentiment is generally favorable, supporting a buy-and-hold strategy for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
